Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

BioPorto - Receives FDA clearance for NGAL test in the US

By HC Andersen Capital
BioPorto

Meet and ask questions to CEO Tony Paré from Bioporto on 11 December at 13:00 CET.

The focus will be on FDA 510(k) clearance for the NGAL test in the United States. This is the first test to aid in assessing AKI (Acute Kidney Injury) risk for patients aged 3 months through 21 years. The test will be marketed as ProNephro AKI™ (NGAL). Bioporto expects that US sales through its distribution agreement with Roche Diagnostics GmbH will begin in the second half of 2024.

Disclaimer: HC Andersen Capital receives payment from Bioporto for a DigitalIR/Corporate Visibility and IR advisory agreement./Claus Thestrup 13:05 8/12-2023.

Recent videos

Remedy Q3’25: Upcoming games in focus
12.11.2025, 11.29 Remedy Entertainment
HCA Morgenbørs 12/11 - Overvejende positive markeder med fokus på FLSmidth, Matas og Schouw & Co.
12.11.2025, 09.42 FLSmidth & Co.
Pierce Group, Audiocast, Q3'25
12.11.2025, 09.00 Pierce Group
Yubico, Audiocast, Q3'25
12.11.2025, 09.00 Yubico
Karnov Group, Audiocast, Q3'25
12.11.2025, 09.00 Karnov Group
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.